Professor Jeremy Chataway MA, PhD, FRCP Consultant Neurologist National Hospital for Neurology and Neurosurgery, (NHNN) Queen Square, University College Foundation NHS Trust and Professor of Neurology, University College, London.

​

After qualifying in medicine at Cambridge and Oxford Universities, and general medical training in London, Professor Chataway specialised in Neurology with posts in Edinburgh, Cambridge and London. He was awarded a PhD from Cambridge University in genetic epidemiology of multiple sclerosis (MS) and took up his post as a Consultant Neurologist in 2001 at The National Hospital for Neurology and Neurosurgery, Queen Square, University College Foundation NHS Trust, London  

​

Professor Chataway is also a general neurologist and sees patients with headache and migraine, stroke and TIA, Parkinson's disease.  He has a particular interest in Multiple Sclerosis and has a national and international reputation in this field.  He is fully familiar with all Disease Modifying Treatments (DMT) and leads a number of clinical trials in Progressive Multiple Sclerosis (MS-STAT2 and OCTOPUS

www.ms-octopus.info).  He works closely with both the UK and US Multiple Sclerosis Societies

​

​

Additional UCL Positions

 

Co-Programme Lead for Neurodegenerative Diseases (NDD) MRC-CTU: 2021-current.

 

Clinical Director Comprehensive Clinical Trials Unit: 2016-2019.

 

International Positions

 

Member: International Advisory Committee on Clinical Trials (IACCT) in MS: 2021-current. This is a major international committee co-sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the National (US) Multiple Sclerosis Society.

 

Member: International Progressive MS Alliance Experimental Medicine Committee: 2018-current.

​

​

Prizes, Awards and Other Honours

 

2021: MS Society Annual Ambassadorial Lecture

 

2015: MS Society Annual Ambassadorial Lecture

 

2014: Winner of the UK MS Society Research Prize (MS-STAT trial, Lancet 2014)

 

2012: Lead Neurologist for the London Olympic Games

​

​

Recent publications

 

Vivien Li, MBBS, FRACP,* Baptiste Leurent, PhD,* Frederik Barkhof, MD, PhD, Marie Braisher, MSc, Fay Cafferty, PhD, Olga Ciccarelli, MD, PhD, Arman Eshaghi, MD, PhD, Emma Gray, PhD, Jennifer M. Nicholas, PhD, Mahesh Parmar, PhD, Guy Peryer, PhD, Jenny Robertson, MPsych(Health), Nigel Stallard, PhD, James Wason, PhD, and Jeremy Chataway, MD, PhD Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple sclerosis. Neurology, 98(18), 754-764. Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple sclerosis. Neurology 2022;98(18):754-64.

 

Palladino, R, Chataway J, Majeed, A and Marrie RA. (2021). Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality. A Population-Based Matched Cohort Study. Neurology 2021;97:e1322-e1333. doi:10.1212/WNL.0000000000012610 C

 

Chataway J., De Angelis F., Connick P, Parker R. A., Plantone D., Doshi A., on behalf of the MS-SMART Investigators. (2020). Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology doi:10.1016/S1474-4422(19)30485-5

​

Palladino R, Marrie RA, Majeed A, Chataway J. Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurology. 2020 ;77(7):820-8.

 

Chan D, Binks S, Nicholas J, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality of life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomized, placebo-controlled trial. Lancet Neurology 2017 16:591-600.

 

Ontaneda D, Fox R, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives Lancet Neurology 2015 14: 208-23.

 

Chataway J., Schuerer N., Alsanousi A., Chan D., MacManus D, Hunter, K Anderson, V Bangham, C.R Clegg, S Nielsen C, Fox N.C, Wilkie D., Nichola, J.M, Calder V.L, Greenwood J., Frost C. and Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014 383:2213-2221.

 

 

All publications see: https://iris.ucl.ac.uk/iris/browse/profile?upi=JCHAT72

​